ASX:LCTLiving Cell Technologies Competitors & Alternatives

Living Cell Technologies (ASX:LCT) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares Living Cell Technologies and Rezolute's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Living Cell Technologies and Rezolute, as provided by MarketBeat.com.

Rezolute has a consensus price target of $0.4650, suggesting a potential upside of 365.00%. Given Rezolute's higher possible upside, analysts plainly believe Rezolute is more favorable than Living Cell Technologies.

Earnings and Valuation

This table compares Living Cell Technologies and Rezolute's gross revenue, earnings per share (EPS) and valuation.

Rezolute has lower revenue, but higher earnings than Living Cell Technologies.

Summary

Rezolute beats Living Cell Technologies on 2 of the 3 factors compared between the two stocks.

Kazia Therapeutics (ASX:KZA) and Living Cell Technologies (ASX:LCT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk.

Valuation and Earnings

This table compares Kazia Therapeutics and Living Cell Technologies' top-line revenue, earnings per share (EPS) and valuation.

Living Cell Technologies has lower revenue, but higher earnings than Kazia Therapeutics. Living Cell Technologies is trading at a lower price-to-earnings ratio than Kazia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Kazia Therapeutics and Living Cell Technologies, as reported by MarketBeat.

Profitability

This table compares Kazia Therapeutics and Living Cell Technologies' net margins, return on equity and return on assets.

Summary

Kazia Therapeutics beats Living Cell Technologies on 3 of the 5 factors compared between the two stocks.

Living Cell Technologies (ASX:LCT) and NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Living Cell Technologies and NovaBay Pharmaceuticals, as reported by MarketBeat.com.

NovaBay Pharmaceuticals has a consensus price target of $1.10, suggesting a potential upside of 1.85%. Given NovaBay Pharmaceuticals' higher possible upside, analysts plainly believe NovaBay Pharmaceuticals is more favorable than Living Cell Technologies.

Earnings & Valuation

This table compares Living Cell Technologies and NovaBay Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

NovaBay Pharmaceuticals has lower revenue, but higher earnings than Living Cell Technologies.

Profitability

This table compares Living Cell Technologies and NovaBay Pharmaceuticals' net margins, return on equity and return on assets.

Summary

NovaBay Pharmaceuticals beats Living Cell Technologies on 2 of the 3 factors compared between the two stocks.

Noxopharm (ASX:NOX) and Living Cell Technologies (ASX:LCT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Earnings & Valuation

This table compares Noxopharm and Living Cell Technologies' gross revenue, earnings per share (EPS) and valuation.

Living Cell Technologies has lower revenue, but higher earnings than Noxopharm. Living Cell Technologies is trading at a lower price-to-earnings ratio than Noxopharm, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Noxopharm and Living Cell Technologies, as provided by MarketBeat.

Profitability

This table compares Noxopharm and Living Cell Technologies' net margins, return on equity and return on assets.

Summary

Living Cell Technologies beats Noxopharm on 3 of the 5 factors compared between the two stocks.

Prana Biotechnology (ASX:PBT) and Living Cell Technologies (ASX:LCT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Prana Biotechnology and Living Cell Technologies' revenue, earnings per share and valuation.

Living Cell Technologies has lower revenue, but higher earnings than Prana Biotechnology. Living Cell Technologies is trading at a lower price-to-earnings ratio than Prana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Prana Biotechnology and Living Cell Technologies' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for Prana Biotechnology and Living Cell Technologies, as reported by MarketBeat.

Living Cell Technologies (ASX:LCT) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and target prices for Living Cell Technologies and Scancell, as provided by MarketBeat.

Profitability

This table compares Living Cell Technologies and Scancell's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Living Cell Technologies and Scancell's gross revenue, earnings per share and valuation.

Scancell has lower revenue, but higher earnings than Living Cell Technologies. Scancell is trading at a lower price-to-earnings ratio than Living Cell Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Living Cell Technologies beats Scancell on 3 of the 3 factors compared between the two stocks.